BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 11719746)

  • 1. Pentobarbital for severe gamma-butyrolactone withdrawal.
    Sivilotti ML; Burns MJ; Aaron CK; Greenberg MJ
    Ann Emerg Med; 2001 Dec; 38(6):660-5. PubMed ID: 11719746
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gamma-hydroxybutyrate withdrawal syndrome.
    Dyer JE; Roth B; Hyma BA
    Ann Emerg Med; 2001 Feb; 37(2):147-53. PubMed ID: 11174231
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management and treatment of gamma butyrolactone withdrawal syndrome: a case report and review.
    Ghio L; Cervetti A; Respino M; Belvederi Murri M; Amore M
    J Psychiatr Pract; 2014 Jul; 20(4):294-300. PubMed ID: 25036586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Withdrawal syndrome after abuse of GHB (Gamma-Hydroxybutyrate) and its physiological precursors - its relevance for child and adolescent psychiatrists].
    Zepf FD; Holtmann M; Duketis E; Maier J; Radeloff D; Schirman S; Wagner A; Poustka F; Wöckel L
    Z Kinder Jugendpsychiatr Psychother; 2009 Sep; 37(5):413-20. PubMed ID: 19739059
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gamma hydroxybutyrate (GHB) and gamma butyrolactone (GBL) withdrawal: five case studies.
    McDaniel CH; Miotto KA
    J Psychoactive Drugs; 2001; 33(2):143-9. PubMed ID: 11476261
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ["Liquid ecstasy": gamma-butyrolactone withdrawal delirium with rhabdomyolysis and dialysis dependent renal failure].
    Supady A; Schwab T; Busch HJ
    Dtsch Med Wochenschr; 2009 Apr; 134(18):935-7. PubMed ID: 19384813
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [GHB withdrawal delirium].
    Stijnenbosch PJ; Zuketto C; Beijaert PJ; Maat A
    Ned Tijdschr Geneeskd; 2010; 154():A1086. PubMed ID: 20132572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The clinical toxicology of γ-hydroxybutyrate, γ-butyrolactone and 1,4-butanediol.
    Schep LJ; Knudsen K; Slaughter RJ; Vale JA; Mégarbane B
    Clin Toxicol (Phila); 2012 Jul; 50(6):458-70. PubMed ID: 22746383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unusual presentation of a patient with GBL withdrawal: a case report.
    Kashyap GL; Patel AG
    Psychiatr Danub; 2011 Sep; 23 Suppl 1():S32-4. PubMed ID: 21894099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Withdrawal from gamma-hydroxybutyrate, 1,4-butanediol and gamma-butyrolactone: a case report and systematic review.
    Wojtowicz JM; Yarema MC; Wax PM
    CJEM; 2008 Jan; 10(1):69-74. PubMed ID: 18226321
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation for the withdrawal syndrome from gamma-hydroxybutyric acid (GHB), gamma-butyrolactone (GBL), and 1,4-butanediol (1,4-BD) in different rat lines.
    Quang LS; Colombo G; Lobina C; Maccioni P; Orru A; Gessa GL; Maher TJ; Carai MA
    Ann N Y Acad Sci; 2006 Aug; 1074():545-58. PubMed ID: 17105952
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inpatient management of GHB/GBL withdrawal.
    Delic M
    Psychiatr Danub; 2019 Sep; 31(Suppl 3):354-356. PubMed ID: 31488752
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A 16-year-old boy with severe gamma-butyrolactone (GBL) withdrawal delirium.
    Zepf FD; Holtmann M; Duketis E; Maier J; Radeloff D; Wagner A; Poustka F; Wöckel L
    Pharmacopsychiatry; 2009 Sep; 42(5):202-3. PubMed ID: 19724983
    [No Abstract]   [Full Text] [Related]  

  • 14. Psychiatric aspects of acute withdrawal from gamma-hydroxybutyrate (GHB) and its analogue gamma-butyrolactone (GBL): implications for psychiatry services in the general hospital.
    Choudhuri D; Cross S; Dargan PI; Wood DM; Ranjith G
    Int J Psychiatry Clin Pract; 2013 Jun; 17(2):154-6. PubMed ID: 23485126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gamma-butyrolactone (GBL) dependence and withdrawal.
    Bell J; Collins R
    Addiction; 2011 Feb; 106(2):442-7. PubMed ID: 20925687
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gamma-hydroxybutyric acid (GHB) in the treatment of alcohol withdrawal syndrome: a randomized comparative study versus benzodiazepine.
    Addolorato G; Balducci G; Capristo E; Attilia ML; Taggi F; Gasbarrini G; Ceccanti M
    Alcohol Clin Exp Res; 1999 Oct; 23(10):1596-604. PubMed ID: 10549990
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical relevance of ethanol coingestion in patients with GHB/GBL intoxication.
    Galicia M; Dargan PI; Dines AM; Yates C; Heyerdahl F; Hovda KE; Giraudon I; ; Wood DM; Miró Ò;
    Toxicol Lett; 2019 Oct; 314():37-42. PubMed ID: 31301370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medical and legal confusion surrounding gamma-hydroxybutyrate (GHB) and its precursors gamma-butyrolactone (GBL) and 1,4-butanediol (1,4BD).
    Wood DM; Warren-Gash C; Ashraf T; Greene SL; Shather Z; Trivedy C; Clarke S; Ramsey J; Holt DW; Dargan PI
    QJM; 2008 Jan; 101(1):23-9. PubMed ID: 18203723
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Acute gamma-butyrolactone poisoning with withdrawal syndrome].
    Chwaluk P; Rejmak G
    Przegl Lek; 2011; 68(8):537-8. PubMed ID: 22010460
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A case of γ-butyrolactone associated with severe withdrawal delirium and acute renal failure.
    Bhattacharya IS; Watson F; Bruce M
    Eur Addict Res; 2011; 17(4):169-71. PubMed ID: 21454980
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.